Drugs / Allogenic placenta derived mesenchymal stem cells
Allogenic placenta derived mesenchymal stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06360861 | Jul 2019 → Mar 2024 | secondary progressive multiple sclerosis | Tehran University of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogenic placenta derived mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06360861 ↗ |
| Modality | Cell therapy | “Allogenic placenta derived mesenchymal stem cells” NCT06360861 ↗ |
| Route | Intravenous | “via intravenous injection” NCT06360861 ↗ |